Heart attack, or myocardial infarction, occurs when blood flow to part of the heart muscle is blocked and myocardial tissue is injured. Coronary artery disease is the main cause. Rapid emergency treatment is critical because delayed reperfusion increases permanent heart damage and mortality risk.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
Human heart muscle cells can regrow after a heart attack; scientists also built a lab-grown sinoatrial node and a beating heart-on-a-chip with cellular-level sensing.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Medtronic reported interim Affera Sphere-9 data showing 65.5% of VT patients were free from recurrence at six months. The FDA granted Breakthrough Device designation for Sphere-9 and approved a U.S. pivotal IDE.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.
Novo Nordisk received FDA approval for a 7.2-mg semaglutide dose marketed as Wegovy HD for adult patients with obesity who have tolerated the standard 2.4-mg dose. The approval came through the FDA's new Commissioner's National Priority Voucher pilot program.
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
Three new CRISPR-based therapies show promise for treating heart failure through mitochondrial enhancement, cystic fibrosis via lipid nanoparticle gene insertion, and elevated cholesterol with single-dose gene editing targeting ANGPTL3.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07285915 |
The Role of Stress in Cardiac Arrest (Cortizol CPR) |
RECRUITING | NA |
| NCT06374277 |
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence |
RECRUITING | NA |
| NCT06280976 |
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) |
WITHDRAWN | PHASE4 |
| NCT06271577 |
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II |
RECRUITING | NA |
| NCT06101862 |
Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome |
RECRUITING | NA |
| NCT05957172 |
Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation |
WITHDRAWN | |
| NCT05720156 |
Immunomodulatory Effects of PCSK9 Inhibition |
WITHDRAWN | |
| NCT05415735 |
Stress Management and Resiliency Training Following Acute Myocardial Infarction |
COMPLETED | NA |
| NCT05305911 |
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI |
RECRUITING | PHASE2 |
| NCT05090618 |
The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population |
COMPLETED |
